First published 10/3/2026, 12:29:15 AM · Last updated 10/3/2026, 12:29:15 AM

P1.11.16 Gut Microbiota: Associations Between Composition and Response to Immunotherapy in Non-Small Cell Lung Cancer

A journal article reporting associations between gut microbiota composition and response to immunotherapy in non-small cell lung cancer. Publisher metadata identifies Elsevier BV as the publisher but provides no additional study details in the supplied source data.

Illustrative image: Algorithm for treatment of patients with non-small cell lung cancer (NSCLC). First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. https://doi.org/10.3390/ph13110373 — Nicola J. Nasser, Miguel Gorenberg, and Abed Agbarya/Wikimedia Commons, CC BY 4.0

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 3/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 4/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The title indicates a possible link between microbiota composition and immunotherapy response in a major cancer type.

Sources

P1.11.16 Gut Microbiota: Associations Between Composition and Response to Immunotherapy in Non-Small Cell Lung Cancer

Report an issue